BamSEC and AlphaSense Join Forces
Learn More

FibroGen Inc

NASDAQ: FGEN    
Share price (12/20/24): $0.40    
Market cap (12/20/24): $40.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.5
from 10-Q 11 pages Fibrogen, Inc. Stock Option Grant Notice
12/34/56
EX-10.4
from 10-Q 9 pages Fibrogen, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.3
from 10-Q 94 pages First Amended and Restated Option Agreement and Plan of Merger by and Among Fibrogen, Inc., Fortis Therapeutics, Inc. and Shareholder Representative Services LLC, as Sellers’ Representative Dated as of June 6, 2024
12/34/56
EX-10.2
from 10-Q 58 pages First Amended and Restated Evaluation Agreement by and Between Fibrogen, Inc. and Fortis Therapeutics, Inc. June 6, 2024 First Amended and Restated Evaluation Agreement
12/34/56
EX-10.1
from 8-K 28 pages Fibrogen, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: April 22, 2024 Approved by the Stockholders: June 5, 2024
12/34/56
EX-10.4
from 10-Q 25 pages Material contract
12/34/56
EX-10.3
from 10-Q 5 pages Fibrogen, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 22 pages Termination Agreement by and Between Fibrogen, Inc. and Astrazeneca Ab Dated as of February25, 2024
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 1 to the Exclusive License and Option Agreement
12/34/56
EX-10.53
from 10-K 3 pages Amendment No. 1 to the Second Amended and Restated Exclusive License Agreement
12/34/56
EX-10.5
from 10-K 7 pages Fibrogen, Inc. Bonus Plan
12/34/56
EX-10.1
from 8-K 8 pages Consulting Agreement 1
12/34/56
EX-10.7
from 10-Q 92 pages Option Agreement and Plan of Merger by and Among Fibrogen, Inc., Fortis Therapeutics, Inc. and Shareholder Representative Services LLC, as Sellers’ Representative Dated as of May 5, 2023
12/34/56
EX-10.6
from 10-Q 60 pages Evaluation Agreement by and Between Fibrogen, Inc. and Fortis Therapeutics, Inc. May 5, 2023
12/34/56
EX-10.5
from 10-Q 164 pages Financing Agreement Dated as of April 29, 2023 Among Fibrogen, Inc., as Borrower, Certain Subsidiaries of Borrower, as Guarantors, Various Lenders From Time to Time Party Hereto, and Wilmington Trust, National Association, as Administrative Agent
12/34/56
EX-10.4
from 10-Q 54 pages Amended and Restated Exclusive License Agreement by and Among Fibrogen, Inc. and Its Affiliates and Eluminex Biosciences (Suzhou) Limited
12/34/56
EX-10.2
from 8-K 7 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 3 pages Material contract
12/34/56
EX-10
from 10-Q 15 pages Fibrogen, Inc. Change in Control and Severance Agreement
12/34/56
EX-10
from 10-Q 5 pages Fibrogen, Inc. Non-Employee Director Compensation Policy
12/34/56